Patients report trouble filling generic liraglutide 3 mg five-pen cartons

People who use generic liraglutide 3 mg for weight management are reporting that they cannot get their prescriptions filled. In a thread in the r/liraglutide community, members describe a supply gap in the five-pen cartons used for the weight-management version of the drug, running through late May and into June 2026 ^[1].

Liraglutide is the molecule sold under the brand name Saxenda for weight management and under a different brand name, at a lower strength, for type 2 diabetes. The 3 mg daily dose is the weight-management strength. Generic versions are sold in the United States, and the thread's title refers to a shortage of generic Saxenda ^[1].

The reports point to a narrow pattern rather than a total gap. The five-pen weight-management cartons were the ones patients said they could not get ^[1]. Two-pen and three-pen cartons, the package sizes associated with the diabetes version of the drug, remained available according to the same accounts ^[1].

Several members said they eventually got their medicine after moving the prescription to a different pharmacy chain, where they were given cartons labeled by Cipla ^[1].

What is not established is why the five-pen cartons are hard to find. There is no official confirmation of a shortage in the accounts, and no manufacturer statement or regulatory shortage listing is described in the thread ^[1]. Whether the gap comes from manufacturing limits, how wholesalers allocate supply, how individual pharmacies place orders, or something else has not been reported. No figures on how many patients were affected, how many pharmacies were involved, or how long any individual waited have been disclosed ^[1].

The reports are patient accounts posted in a public forum. They are not a count of confirmed shortages, and they do not show how widespread the problem is. It also has not been reported whether the same gap affects the 3 mg version sold under a brand name, or whether it is limited to generic cartons.

Why it matters for patients

Liraglutide is a daily injection, so a pharmacy that cannot fill it creates a gap that repeats every day until the prescription is filled somewhere else. The accounts suggest the problem is tied to a specific package size, not to the drug itself: patients reported that the smaller diabetes cartons were still on shelves while the five-pen weight-management cartons were not ^[1]. That distinction matters to anyone trying to figure out whether a pharmacy simply does not carry the product or genuinely cannot order it.

Transferring a prescription to another chain is what several people in the thread said worked for them ^[1]. Transfers take time and depend on the second pharmacy being able to order the product, and the accounts do not say how long the process took or whether everyone who tried it succeeded.

Price and insurance coverage are a separate question. Whether a transferred prescription is covered at the same cost, and whether a different manufacturer's carton is treated the same way by a given plan, has not been reported ^[1].

What happens next

The community accounts describe the gap running through late May and June 2026 ^[1]. No date for when supply is expected to return has been reported. No statement from the manufacturer, from a distributor, or from federal regulators about the five-pen cartons has been reported either, so it is not yet known whether the situation is resolving, holding steady, or widening.